百洋医药携手北京大学国际医院共建精准放疗中心

Core Insights - Baiyang Pharmaceutical has signed a strategic cooperation agreement with Peking University International Hospital to establish a precision radiotherapy center focused on brain tumors [1][3] - The ZAP-X device, operated by Baiyang, is designed to enhance the precision and safety of brain tumor radiotherapy, addressing the increasing incidence of brain metastases in China, which exceeds 1.5 million new cases annually [3] Group 1 - The collaboration aims to create a high-level radiotherapy platform that specializes in the treatment of brain tumors [1][3] - The ZAP-X device features an innovative dual-rotating spherical structure that allows X-rays to target tumors from thousands of non-coplanar angles, concentrating radiation on the tumor while minimizing exposure to surrounding healthy tissue [3] - ZAP-X has received regulatory approval in 24 countries and regions worldwide, with over 5,000 clinical treatments completed to date [3] Group 2 - Baiyang's chairman, Fu Gang, emphasized that this partnership is a significant step towards enhancing the clinical application of advanced radiotherapy equipment and improving access to quality medical resources [3]